Federated Hermes’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-205
Closed -$4.97K 2084
2025
Q3
$4.97K Sell
205
-573
-74% -$9.54K ﹤0.01% 1944
2025
Q2
$12.8K Buy
778
+316
+68% +$5.46K ﹤0.01% 1782
2025
Q1
$8.41K Buy
+462
New +$13.2K ﹤0.01% 1829
2023
Q2
Sell
-12,885
Closed -$437K 2113
2023
Q1
$437K Buy
12,885
+2,710
+27% +$142K ﹤0.01% 1439
2022
Q4
$588K Sell
10,175
-3,224
-24% -$199K ﹤0.01% 1318
2022
Q3
$1.26M Buy
13,399
+13,306
+14,308% +$1.89M ﹤0.01% 1048
2022
Q2
$21K Buy
+93
New +$31.1K ﹤0.01% 1760
2021
Q1
Sell
-2,000
Closed -$2.85M 2238
2020
Q4
$2.85M Buy
+2,000
New +$2.13M 0.01% 956
2020
Q1
Sell
-1
Closed -$1K 2255
2019
Q4
$1K Sell
1
-9
-90% -$4.4K ﹤0.01% 2076
2019
Q3
$3K Buy
+10
New +$3.21K ﹤0.01% 1993
2018
Q2
Sell
-40,000
Closed -$5.85M 2206
2018
Q1
$5.85M Buy
+40,000
New +$6.77M 0.02% 583

Other funds holding CDLX

Federated Hermes's CDLX Position: Q4 2025 in Review

Federated Hermes sold out of Cardlytics (CDLX) in Q4 2025, closing a stake of 205 shares — an estimated $4.97K sold.

Federated Hermes first reported a position in CDLX in Q1 2018 and held it in 11 quarters. The position peaked at $5.85M in Q1 2018. 70 funds tracked by Wall St. Rank hold CDLX as of Q4 2025.

  • Federated Hermes reported no remaining Cardlytics position as of Q4 2025 after selling out during the quarter.
  • Federated Hermes sold 205 Cardlytics shares in Q4 2025, an estimated $4.97K.
  • Federated Hermes first reported a position in Cardlytics in Q1 2018 and held it in 11 quarters.
  • Federated Hermes's Cardlytics position peaked at $5.85M in Q1 2018.
  • 70 funds tracked by Wall St. Rank held Cardlytics as of Q4 2025.

Based on Federated Hermes's 13F filing for Q4 2025, filed 12 Feb 2026.